Preparation of controlled degradation of insulin-like growth factor 1/spider silk protein nanofibrous membrane and its effect on endothelial progenitor cell viability

被引:3
|
作者
Chen, Lifang [1 ]
Huang, Yulang [1 ]
Yang, Rongfeng [2 ]
Xiao, Jian [1 ]
Gao, Jiajia [2 ]
Zhang, Debao [1 ]
Cao, Duanwen [1 ,3 ]
Ke, Xiao [2 ,4 ]
机构
[1] Shenzhen Nanshan Dist Shekou Peoples Hosp, Dept Cardiol, Shenzhen 518057, Peoples R China
[2] Chinese Acad Med Sci, Shenzhen Sun Yat Sen Cardiovasc Hosp, Fuwai Hosp, Dept Cardiol, Shenzhen, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Clin Trials Res Ctr, Nanchang, Jiangxi, Peoples R China
[4] Jinan Univ, Dept Biomed Engn, Guangdong Higher Educ Inst, Key Lab Biomat, Guangzhou 510632, Peoples R China
基金
中国博士后科学基金; 中国国家自然科学基金;
关键词
Controlled-releasing; nanofibrous membrane; degradation; IGF-1; endothelial progenitor cells; TEV protease; ISCHEMIA-REPERFUSION INJURY; MECHANICAL-PROPERTIES; SCAFFOLDS; FABRICATION;
D O I
10.1080/21655979.2021.1982270
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The present study aimed to prepare a kind of controlled-releasing insulin-like growth factor 1 (IGF-1)/spider silk protein nanofibrous membrane using a electrostatic spinning method and evaluated its effect on the cell viability of endothelial progenitor cells (EPCs). Recombinant spidroin named as GMCDRSSP-IgF-1 was electro-spun into nanofibrous membrane which can be degraded by protease and be capable of sustained-release of IGF-1. The membrane can be degraded after being treated with thrombin. The release assay results showed that IGF-1 concentration could be maintained at 20 ng/ml for a long time with treatment of Tobacco Etch Virus (TEV) protease. The viability of EPCs on GMCDRSSP-IgF-1 nanofibrous membrane was significantly increased with the presence of TEV protease. The controlled and sustained release of IGF-1 from the nanofibrous membrane could promote the adhesion and viability of EPCs. In summary, the nanofibrous membrane that exhibits controlled degradation and sustained release of IGF-1 was prepared with electrostatic spinning from genetically modified recombinant spider silk protein. The nanofibrous membrane exhibited good blood compatibility and cytocompatibility. With the presence of TEV protease, the sustained-release of IGF-1 significantly promoted the adhesion and viability of EPCs. The new nanofibrous membrane can be potentially used as a scaffold for EPCs culture in vitro and future in vivo studies.
引用
收藏
页码:8031 / 8042
页数:12
相关论文
共 50 条
  • [31] Insulin-like growth factor binding protein-3 and transforming growth factor-beta 1 in kidney endothelial cells
    Giannini, S
    Cresci, B
    Pala, L
    Galli, G
    Rotella, CM
    [J]. DIABETOLOGIA, 1996, 39 : 1117 - 1117
  • [32] No effect of exercise on insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in postmenopausal women: a 12-month randomized clinical trial
    McTiernan, A
    Sorensen, B
    Yasui, Y
    Tworoger, SS
    Ulrich, CM
    Irwin, ML
    Rudolph, RE
    Stanczyk, FZ
    Schwartz, RS
    Potter, JD
    [J]. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (04) : 1020 - 1021
  • [33] The raf-1 protein mediates insulin-like growth factor-induced proliferation of erythroid progenitor cells
    Sanders, MR
    Lu, HW
    Walker, F
    Sorba, S
    Dainiak, N
    [J]. STEM CELLS, 1998, 16 (03) : 200 - 207
  • [34] ENHANCING VASCULAR ENDOTHELIAL REPAIR IN THE SETTING OF INSULIN RESISTANCE: EFFECTS OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-1
    Aziz, A.
    Yuldasheva, N.
    Smith, J.
    Haywood, N.
    Paul, C.
    Cubbon, R.
    Kearney, M.
    Porter, K.
    Wheatcroft, S.
    [J]. HEART, 2013, 99
  • [35] Endothelial Cell Insulin Sensitivity and Nitric Oxide Bioavailability Are Regulated by Insulin-Like Growth Factor-1 and Insulin Receptor Levels
    Viswambharan, Hema
    Imrie, Helen
    Abbas, Afroze
    Gage, Matthew
    Kahn, Matthew
    Rajwani, Adil
    Yuldasheva, Nadira
    Xuan, Shouhong
    Baliga, Vivek
    Surr, Jessica
    Cubbon, Richard
    Wheatcroft, Stephen
    Kearney, Mark
    [J]. CIRCULATION, 2010, 122 (21)
  • [36] Clinical significance of type 1 insulin-like growth factor receptor and insulin-like growth factor binding protein-3 expression in squamous cell carcinoma of head and neck
    Jun, H.
    Chang, M.
    Ko, Y.
    Ahn, Y.
    Jeong, H.
    Son, Y.
    Baek, J.
    Park, Y.
    Park, K.
    Ahn, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A Prospective Study of Insulin-Like Growth Factor 1, Its Binding Protein 3, and Risk of Endometriosis
    Mu, Fan
    Hankinson, Susan E.
    Schernhammer, Eva
    Pollak, Michael N.
    Missmer, Stacey A.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2015, 182 (02) : 148 - 156
  • [38] Regulation of human dermal papilla cell production of insulin-like growth factor binding protein-3 by retinoic acid, glucocorticoids, and insulin-like growth factor-1
    Hembree, JR
    Harmon, CS
    Nevins, TD
    Eckert, RL
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1996, 167 (03) : 556 - 561
  • [39] Effect of thyroxine replacement on creatinine, insulin-like growth factor 1, acid-labile subunit, and vascular endothelial growth factor
    Schmid, C
    Brändle, M
    Zwimpfer, C
    Zapf, J
    Wiesli, P
    [J]. CLINICAL CHEMISTRY, 2004, 50 (01) : 228 - 231
  • [40] Age-dependent impairment of endothelial progenitor cells is corrected by growth hormone mediated increase of insulin-like growth factor-1
    Thum, Thomas
    Hoeber, Sarah
    Froese, Sabrina
    Klink, Ivonne
    Stichtenoth, Dirk O.
    Galuppo, Paolo
    Jakob, Marten
    Tsikas, Dimitrios
    Anker, Stefan D.
    Poole-Wilson, Philip A.
    Borlak, Juergen
    Ertl, Georg
    Bauersachs, Johann
    [J]. CIRCULATION RESEARCH, 2007, 100 (03) : 434 - 443